InvestorsHub Logo
Post# of 252254
Next 10
Followers 21
Posts 2057
Boards Moderated 0
Alias Born 06/14/2007

Re: DewDiligence post# 173436

Thursday, 01/30/2014 1:42:54 PM

Thursday, January 30, 2014 1:42:54 PM

Post# of 252254
I'm going to guess she's talking about this statement:

“The availability of three-times-a-week COPAXONE® 40 mg/mL is a significant advancement for patients as they now have the option of effective and safe treatment with COPAXONE®, while reducing the number of injections by 60 percent,” said Omar Khan, M.D., Professor of Neurology and Chair of the Department of Neurology, Wayne State University School of Medicine, Detroit, MI. “Patients in the U.S. can now benefit from an improved dosing regimen without compromising the known benefits of COPAXONE®.”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.